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LH&fives. This sFudg sought to evaluate the r0k and ittcre- 
mental value wf atr0pine in a large patient gmup undergOing 
dobuhmlue press ~h~~~j~~p~y. 
I& ‘The use Of atr0pitte to pntentiate dobutamine 
stress is rtot staudard pructice~ Altltough the utility Of atmpine 
has been detihed, data On its Iticremental value remain Bimited 
an exist fOr a r0utine clinical practice setting. 
. DOhuhmiue stress e&cardiography was performed 
in 1,171 patients with use Of a standard prot0&. Atropine 
(maximal dOse 2.0 mg) was given to 299 pattents (26%) who did 
not attaiu tatget heart rate. Co:awoaty attgiOgruphy was performed 
in 10 p&tests (46 received a&opine), 148 ofwlrom were found TV 
have siguiticrtrtt corutmry artery disease (L7M diameter stetaosis 
in a maor epicardial vessel, LW% stenosis POr left main c0romuy 
artery disease). All tests were reviewed iudepettdetttly by experi- 
eueed observers. 
induced Esrhcmia devetopeti~ 70 (DA) required atnqtine beTcue 
ischemia became evident. Sensitivity Rt detection OT signibnt 
coronary artery disease was !W% with dolmtamine atoue and 95% 
after the addition Of atropine. In 66 paFieuts 6th nOrmal nall 
motion at rest, test sensitivity was 65% before red &% after 
a&Opine was given. Atropiae use did nut compromise test sue& 
ficity* New diagnnostie ~~~o~attO& was &t&ted in Ztl (§tt%) of 4O 
putieuts with angiograpkiic coronary artery disease given atropiue. 
Fropartioustely more patients with single-vesset disease required 
a&opine before att ischemic resp~ttse was observed, this 
appeared related to the higher iscltemic tureshold iu t&se 
patients. 
Resuks. There were ~0 mJOr adverse events. Patients receiving 
atrpitte Lad a hmer rest heurt rate (65 VS. 74 beats/mitt, p 6 
%tWl) and, mOre often received beta+tdwuergir Mockiug agents 
(4% vs. I&, p < OAltktM). Of 444 patients in when stress- 
Concfmim. ~u~e~~tion of heart rate had a modest ingu- 
en&W On the Overall diaguostic sensitivity of d0butamine stress 
~~~a~(io~~p~y in our study cohort. DOwever, it wus particu- 
larly helpful in putieuts receiving beta-t&t&et% asd thuse with 
milder ntronaty disease. Despite the use Of 2 t mg Of altlrapine in 
some patients, this incremental value was not achieved at the 
expense af :;rCty. 
[J .&tt Cdi Cmfid l996;28:5Sl-7) 
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tiate dabutanrine st-ress is not standard practice (9,X!), possibly 
because initial validat.imn studies have documcnte.d high diag- 
nostic sensitivity without the need for a supplementary agent 
(9,3). 
Dobutamiuc strt~s echocardiogranhy has become an cstab- 
lished noninvasivc test for diagnosing coronary artery disease 
(l-3). Rcccntly, M&kill et al. (4) proposed atropine USC to 
augment pharmacologic stress. Because induction of ischemia 
by r9&tl,ut~tt~litlC IXliCS 1XKlly 011 itdCfjt%tC ChilXlOt~~~9~~ (S-7j1 
atropinc should enhance the diagnostic sensitivity of Qbut- 
amine stress echocardiography. Nowever, data supporting the 
incremental value of atropine use arc limited, do not exist for 
a routine clinical practice ond primarily reflect singtc-center 
experience (4,X). Other investigators remain less convinced of 
the impottance of heart rate as a determinant of optimal stress 
levels during dobutamine echocardiography (9). A review of 
rcccnt publications reveals that the use of atropinr to p&x- 
Tia principal purpose of this investigation. which reviews a 
iarge experience with dobut;unine-atropiill~ stress tcsting~ was 
to determine the role of adjunctive atropine rise in a cohort 
represent:?tive of routine stress echocrdrdiugraphic practice, 
Because benefit should be defined in the context of potential 
adverse eQcts (12.12), the issue of test safety was also 
examined. 
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The study cohort included 1,971 consecutive patients who 
had clinicalfy indicated dobutaminc stress echocardio~r~~hy at 
the Mayo Clinic from May IY!K! TV, Februaty ‘1994; 572: (74%) 
received dobutamine on9y (group 19, and 39 (26%) received 
dobutamine and atropine (group 99). Cardioactive medicatknts 
wcrc not discontinued before testing. Clinica9ly i~ndicated 
coronary angiography was performed in 137 group I (96%}~d , 
stress p&&, ‘Fhc implementation of dobutnminr: stress 
ecllucardiography in our laboratoq has previously been de- 
scribed (13). Dobutamine was infused incrementall;v from 5 to 
~$0 pgJqg body weight per min. If the heart rate was withirt 111 
&^;\:5 of’ the tsrget value (85% of predicted maximum for age)t), 
the iafwh was hcreased to 50 pgkg per min. Othenvise, 
atropine sulfate was administered intravenously in 0.25-mg 
increments at I-min intervals (to a maximal total dose of 
1.0 mg during the first 8 months of the study period and 2.0 mg 
thereaft@ if there were no specific contraindications. Dobut- 
amine infusion was continiled during atropine administration. 
End points for lest termination were 1) attajnment cd target 
]ycart riitc, 2,) conlpletiorl of slrcss protocol, and 3) obvious uew 
regional wall motion abnormalities, In the absence of these 
end points, the test was terminated, at the discretion of the 
ph$cian, iC there was vcrnricular rachycardia, sustained su- 
praventricular tachyarrhythmia, a subsrantial increase or de- 
crease in blood pressure or intolerable symptoms. 
Four standard imaging planes were digitized at baseline, 
low dose infusion (10 &kg per min), prepeak heart rate 
(typically 10 to 20 beatsimin below maximal hetrt rate) and 
peak heart rate. These four images and the apical long- and 
short-axis views were also recorded on 0.75in. videotape. 
Patients were routinely observed for 30 min after discontiau- 
atinn of stress testing. 
Interpretation. Echocaidingraphic images were reviewed 
by an experienced stress echocardiographer who was unaware 
of the clinical data. Wall motion in each of the 16 segments 
of the left ventricle was scored semiquantitatively as follows: 1 = 
normal or hyperkinetic; 2 = mild to moderate hypokicesia; 3 = 
severe hypokinesia or akinesia; 4 = dyskinesia; and 5 = aneurysm 
(14). Nonvisualized segments were not scored. An ischemic 
response was diagnosed if stress induced an increase in wall 
motios score in one or more segments, with the exception of a 
change from akinesia to ,dyskinesia (15). For correlation of 
an&graphic and echocardiographic data, either a rest nr a 
strcss&ducible wall motion abnormality was considered indica- 
tive of coronary disease. Segments were assigned to a vascular 
supply on the basis of a previously described model (13) The 
heart rate at which wall motion abnormalities developed (“isch- 
cmic threshold”) was recorded, Segmental scores were sutnmed 
and divided by the number of visualized segments to yield a wall 
motion score index. Left ventricular ejection fraction was cab- 
lated (16) or estimated visually ( 17). 
Coronary angiogqhy. Coronary angiography was pcr- 
formed by the Judkins technique. Visual estimation of percent 
coronary lumen diameter narrowing was coded by consensus of 
two angiographers in a prospectively maintained data base. 
Hemodynamically significant coronary disease was defined as 
~70% stenosis of a major epicardial artery or primary branch 
or ~50% narrowing of the left main stem. Multivessel disease 
was diagnosed if two or more maior epicardial vessels or the 
left main coronary artery was significantly stenosed. 
Statistical analysis. Echocardiographic data were prospec- 
tively entered into a relational dais base (SAS, Version 6.9). 
Categoric data were reported as percentages and continuous 
data as mean value t SD. Categoric variables were com,pared 
by the chi-square test, and continuous data were analyzed by 
the two-sample Wilcoxon rank sum test. Likelihood of occur- 
rence of a variable of interest was calculated as an odds ratio 
with corresponding 95% confidence inten&. Stepwisc logisric 
regression analysis was used to identify variables predictive of 
ventricular arrhythmia occurrence. Variables used in this imnth- 
ysis are identified in Table 1. The ability of the ischemic 
threshold to discriminate between single- and multivessel 
disease was assessed using receiver operating characteristic 
(ROC) curve analysis. An appropriate cutoff of the ischrmic 
threshold was chosen at the point where sensitivity was approx- 
imately equal to specificity. Differences were considered sig- 
nificant at p < 0.05. 
&?SdkS 
Baseline characteristics. There were 413 men and 756 
women (mean age 6Y 4 12 years, range 26 to 100). Indici~tions 
for dobutamine stress echocardiography were preoperative 
assessment in 492 (42%) patients; evaluation of coronary 
artery disease in 39X (34%); and assessment of chest pain, 
dyspnea or left ventricular dysfunction in 281 (24%). The 
clinical profiles of groups I and II were similar (Table 1). There 
were small differences in age, rest ejection fraction and ‘wall 
motion score index. The most striking difi’erencc between the 
groups was more frequent use of beta-adrenergic blocking 
agents in group II patients (49% vs. 14%* p < 0.0001). 
Feasibility of dobbutamine-atropine stress testing. The 
mean atropine dose was 0.6 mg; 192 patients (64%) received 
doses ~0.5 mg of a&opine, and 20 (7%) were given >l.O.mg. 
Target heart rate was achieved in 6% group I (69’ 3) and 203 
group II (68%) patients. The end point of target hcnrt rate:, 
peak dose infusion or induction of new wall motion ahnorm& 
ities was rezalized in 93% (807 of 872) and 96% (258 of 299) of 
patients in groups I and II, respectively. 
Nemodynamic respa?ase. Group II patients had a lower rest 
heart rate than group I patients (65 ? 1 I vs. 74 2 I2 beatsimin, 
p < O.UOOl). Mean heart rate in group II hefore administration 
of atropine was lower than the peak heart rate attained with 
dobutamine in group I (94 2 20 vs. I27 t 18 beats/min, p < 
OMOI). After a&opine, there were no significant differences in 
heart rate and rate-pressure product between the two groups. 
Mean blood pressures in group I and II patients at rest (1Otl vs. 
98 mm Hg) and ar peak stress (87 vs. ‘31 mm Idg) were also not 
significantly diRcrcnt, 
Detectinn cd coronary artery disease. Tbc pmportion of 
patients with angiographic coronary disease was 79% (108 of 
137) in group I and 87% (40 of 46) in group II (p = 0.23). and 
the incidence of multivessel disease in group 1 (79 [73%] of 
108) and group II (30 [7S%] c;f 40) patients with angiographic 
disease was similar. Abnormal rest wall motion was present in 
IO5 patients (76 in group I, 2Y in group II) with coronary 
disease. New wall motion abnormalities were observed during 
dobutamine infusion in 65 of these patients (47 in group I, 18 
in group II) and in an additional 10 patients after atropine was 
giveti. Among patients with normal rest wail motion, new wall 
motion abnormalities were induced by dobutamine in 2X (26 in 
group I, 2 in group II) and by atropine in another 8. Table 2 
shows the sensitivity and specificity of &butamine-&opine 
stress echocardiography for the detection of coronary disease 
in all patients who underwent angiography and in the subset 
with normal rest wall motion. The value of atropinc was most 
cvidcnt in the latter group. No false positive test results were 
attributed to a&opine use. 
Detection of isclemia. Stress testing induced ischemia in 
329 group I and 115 group 11 patients. In the latter group, 45 
patients had new wall motion abnormalities first noted during 
dobutamine infusion, whereas in 70, ischemia developed only 
after atropine was given. Therefore, 16% (70 of 444) of all 
patients who had an ischemic response required atropine 
before myocardial ischemia became evident. The ischcmic 
thresholds in groups 1 and 11 were similar (I 11 2 7,o and I10 2 
22 beats/min, respectively). 
hong group II patiunts with i~ngir~gmphicall~~ detected 
disease, ischemic wall motion abnormalities developed after 
atropine in 5W% (20 of JO). Twelve oF these 20 patients had 
abnormal rest wall motion; in these patients with presumed 
previous infarction: new dyssynergic regions bccamc. evident 
after atropine administration. Of these, seven regions were adja- 
cent to previously infarcted areas, suggesting peri-infarction isch- 
emiar in five patients, new wall motion abnormalities occurred 
remotely, confirming multivessel disease. Of interest, in two of 
thcsa: five : dtientr;, the new dayssynergic regions aplnnred in a 
different vascular territory after dobutamine had induced a mild 
wall motion abnormality. Eight patients had normal wall motion 
at rest and a negative test response until after atropittc was given. 
Of tlrcsc eight psticnts, thtee had multivc&sel coronary disease, 
and five had singlwe& disease (left anterior descending coro- 
nary artery stentosis in one. circumliex coroniiry artery stenoses in 
three, right corowdry arteT stenosis in one). The lesion sites were 
proximal in four of these eight patients and included a 70% ostial 
left anterior descending artery stenosis in a patient who had 
previously undergone stberectomy. 
Induction of ischemia in single- aad multivessel disease. 
Ischemic segmental wall motion appeared during dohutamine 
infusion in 72 of 308 group I patients with angiographically 
defined coronary artery disease; of these, 16 had single-vessel 
disease, and 56 had multivessel disease. Ischcmia occurred in 
38 of the 40 group II patients with coronary disease. After 
these 38 patients received &opine, ischemia developed in 8 of 
IO with single-vessel disease and 10 of 28 with multivessel 
disease (Fig, 1, top). Therefore, in the entire angiographic 
subset of patients with detectable limitation of flow reserve, 
31% of patients with single-vcsscl and 12% with multivessel 
disease required the addition of atropine to induce ischemia 
(Fig. 1, bottom). 
The increased likelihood (odds ratio [OR] 7;2, 9% confi- 
dence interval [CIJ I.3 to 40.7) of ischemia developing o$ly 
after a&opine in group II patients with single-vessel disease 
was not explained by beta-blocker therapy-50% (5 of IO) bf 
patients with single-vessel and 57% (16 of 28) with multiv&$$ 
disease were receiving this medication (p = &70). The ‘r&k: 
,i ..I’: p, .,’ 
Single vessei CAD Multivessel CAD 
1 
Single vessel CAD Mukivessel CAD 
Pigua 1, Top, Distribution of angiographic coronary artery disease 
(CAD) in 38 group I1 patients with inducible ischemia during 
dobutamine-a&opine stress cchocardiography. fschemia developed 
after atropine administration In a significantly higher proportion of 
patients with single-vessel coronary artery disease. Bnbtom, Among the 
llb patients with augiographic coronary artery disease and stress- 
inducible ischemia, atropine was used relatively more frequently in 
patients with single-vessel coronary artery disease. Open ban = 
&hernia before atropine; hatched bars = ischemia after atropine. 
heart rate (65 i 12 vs. 64 i: 10 beats/min), preatropine heart 
rate (93 -+ 19 vs. 91 t 19 beatsimin) and peak heart rate 
(124 2 21 vs. 12.5 i 15 beats!min) were similar in both groups. 
Patients with single-vessel dLt:asc, howcvcr, tended to have a 
higher ischemic threshold (I 1~’ fi 24 vs. 95 t- 20 beats,‘min, p = 
U.05). The area under the RC9C curve was 0.71 (SE 0.09>, 
indicating a discriminant ability better than chance. Seven 
(70%) of 10 patients with single-vessel disease manifested 
ischemia at a heart rate 2110 beatsimin compared with ‘7 
(25%) of 28 with muitivessel disease. 
Patients receiving beta-binckers. 0f the entitc study co- 
hort, patients taking beta-blockers were more likely to receive 
atropine (54% [147 of 2711 vs. 17% [152 of 9001, p < 0.0001). 
Ischemia developed after the addition of atropine in propor- 
tionately more group II patients receiving beta-blockers (61% 
vs. 40%, p = 0.03). There were no significant differences in age, 
gender, previous myocardial infarction, rest wall motion score 
index or degree of coronary disease (in 34 patients who had 
angiography) between the 61 group II patients with and the 54 
without beta-blockers, implying that the former were unlikely 
to have less coronary disease. 
Tahie & Incidence of Adveme Effects in 1 .I71 Patients Undergoing 
Dobutamine Stress Echoeardiogmphy -~ --- - 
GAup 1 Gr1Nip II 
(E = 8721 , (n = EJ9) p Valus 
!VLUlSi%d 73 (8) 38(13) 0.03 
Hradac~te 66 8 B (9) o/a 
PYtp~t”ti~JllS S6 (10)  13 (8)  0.27 
Chest pain 152 (17)  55 (18)  0.71 
@Spi?CX 517 (Yf 14 (I) 0.01 
Lightheade,dness 41. is? 38 (6) 0.37 
Tremor or shivering St (54) 3’(H) 0.48 
Paroxysmal atriai fibrillation $4 (5) 8 (3) 0.09 
Supravcntria~lar tachycardio 95 (11) Z(7) 0.06 
Complex ventricular ectopic heats 115 (14) 31 (IQ) t.m 
Ncrsustained ventricular !achycardia 6.5 (7) 7 12) 0.001 -~------- --........-..v-v--w- 
Ikua presented arc number (W:) of patients. Group 1 = dohiltamine only; 
Gmup II = dnhulamine and atropinc. 
Adverse effects, With the c,xception of nausea, atropine use 
was not associated with more adverse effects (Table 3). Ar- 
rhythmias necessitated test termmatron in 2X group I (2.4%) 
and 3 group II (1.0%) patients without a defined end point 
(p = 0.14). Nonsustained ventricular tachycardia developed in 
more patients in group I (p = 0.001). §ustained ventricular 
tachycardia did not develop in either group. Acute urinary 
retention, visual disturbance and neurologic dysfunction were 
not observed after stress testing. The incidence of adverse 
effects in patients receiving Cl.0 mg (n = 229) or rl.0 mg of 
atropine (n = 20) did not differ. 
By stepwise selection of covariates, a&opine usage and rest 
wall motion score index were found to be significant indepcn- 
dent predictors of ventricular tachycardia, A&opine usage was 
negatively associated with ventricular tachycardia (QR 0,31, 
95% CI 0.14 to 0.69, p = 0.004), and a rest wall motion score 
index :>I .l was a positive predictor of this arrythmia (OR 2.53, 
95% CI 1.52 to 4.14, p = 0.0003). Group II patients who had 
ischemic wall motion abnormalities before atropine adminis- 
tration (n = 45) were ii3 more prone to complications than 
those with ischemia after atropine (n = 72). Myocardial 
infarction: unstable angina, cardiac arrest or death did not 
occur in either group. 
Discussion 
The present study dctines the role of atropine supplemen- 
tation in a large consccutivc series of patients undergoing 
routine dobutamine stress e;hocardiography. Atropine was 
required in one in four patients because of a suboptimal stress 
response. Its use permitted attainment of a heart rate end 
point in 69% of patients compared with 52% before a&opine 
administration. A&opine use increased diagnostic sensitivity 
for ischemia by 164il and for coronary artery disease by 5%. 
Chronotropic augmentation was of greatest value in patients 
taking beta-blockers, those with single-vessel disease and those 
with normal rest wall motion. In 50% of angiographically 
examined patients receiving a&opine, new regions of ischemia 
(which in every case carrespcmded with significant coronary 
stenosis} were appreciated. 
~~~~a~i~~ with p&cm wo& McNelll et al. (4) found 
that atropinc use i.n 49 of 30 consecutive patients who under- 
went coronary arteriography increased the overall sensitivity of 
dobutaminc stress eshQcardiography from 32% ro 7%* After 
atropine administration, additional diagnostic information was 
obtained in 20 of 31 patients with coronary disease. The benefit 
of atropine use in that study was more impressive than in the 
present study became 80% of the patients were receiving 
beta-blockers. Despite atropine use, test sensitivity in the study 
by fv¶cNeill et al. (4) was only 70%~~ probably reflecting the 
preponderance of patients with single-vessel disease. In con- 
trast, previous studies using dobutamine as the sole stressor 
agent reported diagnostic sensitivities of up to %%I (3). The 
higher test sensitivity in these as well as in the present study 
may be explained by the greater prevalence of multivessel 
disease and the inclusion of many patients with rest dyssynergy. 
Test specificity was relatively low in our study because 
patients with “cardiomyopathic” ventricles were not excluded 
-3r analyzed differently and because of posttest referral bias. 
Marcovitz and Armstrong (3) reported a similarly low speci- 
ficity of 66% in their study population, 62% of whom had rest 
dyssynergy. Other investigators described test specificity only 
in patients with normal rest wall motion (1) or treated myo- 
pathic ventricles ditferently (18). With criteria equivalent to 
those of Sawada et al. (I), sp:cilidty in our study was 87%. 
Importantly, this specificity was not compromised by atropine 
use (4). 
Detection of single-vessel disease. Thhc known lower sensi- 
tivity of dobutamine stress testing for detection of milder forms 
of coronary disease (19) may be enhanced by synergy with an 
agent such as dipyridamole (20). The present study suggests 
that atropine usage may likewise improve diagnostic sensitivity. 
The specific value of a&opine is probably related to the 
generally higher ischemic threshold in patients with single- 
vessel disease (21), particularly if this threshold is not attain- 
able with high doses of dobutamine. Segsr et al. (22) suggested 
that multivessel disease was likely to be present if new wall 
motion abnormalities occurred at a heart rate <I25 bcatslmin. 
In the present study, a heart rate of 110 beats/mm better 
discriminated single- and multivessel disease. The absence of a 
@hreshold heart rate that perfectly dichotomizes these groups 
may reflect the dependence of ischemic threshold on other 
factors, such as collateral circulation and the limitations of 
visual estimation in predicting physiologically important coro- 
nary stenoses (23,24). 
Atrogine use im patients receiving beta-blockers. bwada 
et al. (1) reported that beta-blockade during dobutamine 
echocardiography did not compromise test sensitivity despite 
significant limitation of chronotropic response but acknowl- 
edged the possible confounding influence of more severe 
coronary disease in Patients receiving beta-b!ockers. In a 
crossover study by Pioretti et al. (X)> atropine induced new 
ischemic wall motion abnormalities in I2 of 15 patients during 
beta-blockade and in only 2 of 14 patients during the drug-free 
period. Our observations, arrired at by determining ischemic 
threshold during pharmacologic stress, provide further support 
for the e&cac;rr of atropine in patients receiving beta-blocker 
therapy Although nearly 50% of the patients taking beta- 
blockers in this study required supplementary attopine for 
optimization of diagnostic sensitivity, atrdrpine was also needed 
in 30% of the patients with reduced chronotropic rosponsive- 
ness to dobutamine (18) who were taking neither beta-blockers 
nor calcium channet blockers. 
Mechanisms dischernia in&don by atropine. The equiv- 
alent mean ischemic thresholds in groups I and II suggest that 
it is immaterial whether dobutamine alone or an atropine- 
dobutamine combination is used, provided that an adequate 
heart rate respomsc can be achieved, In botfi clinical (21) and 
experimental (6) studies, tachycardia has heen shown to be an 
important determinant of inducible ischemia during dobut- 
amine infusion. By contrast, Santiago et al. (9) found no 
significant differences in peak heart rate but equivalent test 
sensitivity in the pa&t groups receiving the drug in a dosage 
of ~30 @g/kg per min and surmised that attained heart rate 
was “not a useful end point” for dobutrtmine stress echocardi- 
ography, Wowever, that study did not involve atropine use and 
did not account for factors important iii the ischemic response 
other than the angiographic severity of &ease. Moreover, 
administration of beta-blockers was routinely discontinued 
before testing, a practice not followed by most laboratories 
j1,3,13,25). 
Although induction of ischemia by atropine is primririly 
related to tachycardia-mediated increase in metabolic demand 
and myocardial tension (3t$ there may be a role for direct 
anticholinergic modulation of left ventricular contractility (27). 
Reecntly, Landzberg et al. (28) showed that intracoronary 
infusion of atropine potentiated peak rate of increase of left 
ventricular pressures (-+dPfdt) by 25% during dobutamine infu- 
sion. In addition, atropine may infuence coronary tone, although 
this has been demonstrated only in animal studies (29). 
Safety issues. The present study afitms the safety of 
dobutamine-atropine stress testing as previously reported 
(4,30-32). Despite theoretic concerns (33), stropine use was 
not as&i&cd with an excess of tachyarrhythmias. Neariy 50% 
of our patients who had atropine were receiving beta-blockers, 
which are known to reduce ventricular irritability (34). The 
t,herapeutic window of atropine may also be wider iu these 
patients because excessive tachycardia is curtailed (35). Thesti 
observations ccrrnmend atropine use as a means of circumvent- 
ing the irnpcmtical and potentially hazardous practice of 
withdrawing beta-blockers before stress testing (36) 
In our study, atrapine was used even in patients with mild 
wall motion abnormalities if the test was otherwise uncompli- 
cated. This approach appears to be safe (?.,30), reduces equiv- 
ocal wall motion assessment and may increase recognition of 
multives& disease. 
Doses of atropinc >I mg were used in 7% of group II 
patients, Because of differences in body weight (37) and 
pharmacodynam;c response (38), higher atropine dosage may, 
be required in some patients, In particular, patients with heart, 
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disease ma! have abnormal parasympathetic cardiac control 
and less c;lrdiaa~crelcratilln with equivalent doses of atropine 
(39,4(1). C&asiooal USC of higher doses of atropine did not, 
however, compromise the safety of the test in these patients, 
Notably, central nervous system toxicity which has been 
reported with therapeutic doses of a&opine in hypersensitive 
and older patients after stress e~h~ardio~a~hy (11,41), was 
not observed in our elderly cohort. 
Study limihtiors. There is inherent bias in reporting the 
value of atropine in patients receiving the drug when it tends to 
be given if an end point is not reached with dobutamine. When 
appropriate, we have attempted to avoid this by describing the 
incremental value of a&opine in the context of ai1 patients 
receiving dobutamine. The manner in which the test is per- 
formed and reviewed in our institution (i.e., continuous tape 
recordings arc routinely reviewed to determine ischemic 
threshold) should also reduce this potential for bias. 
As in other reports, the sensitivity and specificity of stress 
echocardiography in our study are imfiuenced by referral 
patterns that select patients with a high posttest prui?ability of 
coronary artery dbcase ior angiography. However, the purpose 
of this study was to define the additional value of atropine 
supplementation, and any posttest referral bias should have no 
differ&al effect on the results observed with and without 
atropine. We are also aware of the imperfect correlation 
between well motion changes and coronary aagiographic ap- 
pearance (Z,24), Nevertheless, the angiographic interprera- 
tion in this study is the most widely used worldwide and is 
based on methods established by large multicenter trials 
comparing medical and surgical treatment of coronary artery 
disease <‘2.43), the results of which have largely influenced 
clinical d&ion making. Intracoronary ultrasound mcasure- 
merits have also shown that lumen diameter and cross-sectional 
area (and preSUmblg Row reserve) may be underestimated by 
quantitati;ic: angiogmphy (44). More recently, Folland et al. (4s) 
demonstrated that the functional significance of coronary steno- 
ses in patients with single-vessel disease was better predicted by 
visual analysis than by quantitative methods. 
Because 3 time lag to onset of the central nervous system 
effects of atropine is recognized (46), some anticholinergic side 
effects may have been underreported at the time that patients 
were dismissed from the stress laboratory. All patients, how- 
ever, were seen by a physician at our institution within 24 to 
48 hl and no significant complications were reported within this 
time frame, Moreover, the dramatic features of central anti- 
cholincrgic syndrome generally become &anifest early after 
‘intoxication (47-49) and are unlikely to be overlooked. 
GoneIusions. The present study defines the role and ben- 
efit of a&opine use in a large stress echocardiographic practice. 
Although the incremental diagnostic value of chronotropic 
augmentation in our study cohort was relatively modest, atro- 
pine was frequently essential for achievement of an adequate 
stress level, particularly in patients receiving beta-blockers, and 
for detection of milder forms of coronary artery disease. This 
incremental value was paralleled by a remarkable degree of 
safety. 
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